VanEck Biotech ETF
BBH
78 hedge funds and large institutions have $63.7M invested in VanEck Biotech ETF in 2019 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 26 reducing their positions, and 13 closing their positions.
1% less call options, than puts
Call options by funds: $2.85M | Put options by funds: $2.87M
0.93% less ownership
Funds ownership: 20.54% → 19.61% (-0.93%)
7% less funds holding
Funds holding: 84 → 78 (-6)
18% less capital invested
Capital invested by funds: $78M → $63.7M (-$14.3M)
38% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 13
69% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$2.84M |
| 2 |
Jane Street
New York
|
+$1.29M |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$340K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$336K |
| 5 |
MJRIC
Mogy Joel R Investment Counsel
Beverly Hills,
California
|
+$155K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TIA
Traphagen Investment Advisors
Oradell,
New Jersey
|
-$6.34M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.25M |
| 3 |
AFG
Albion Financial Group
Salt Lake City,
Utah
|
-$1.24M |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$823K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$640K |
BBH Hedge Fund Activity: Q3 2019 in Review
78 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q3 2019, worth a combined $63.7M — down 18% from $78M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of BBH and 8 opened new positions — a net loss of 5 holders — while 26 trimmed existing stakes and 8 added.
The largest buyer was Virtu Financial, opening a new position worth an estimated $2.84M. The largest seller was Traphagen Investment Advisors, exiting entirely with an estimated $6.34M sold.
- 78 institutional investors held VanEck Biotech ETF (BBH) as of Q3 2019, down from 84 in Q2 2019.
- Funds reported $63.7M of VanEck Biotech ETF stock for Q3 2019, down 18% quarter-over-quarter.
- 8 funds opened new VanEck Biotech ETF positions in Q3 2019 and 13 closed out, a net change of -5 holders.
- The largest VanEck Biotech ETF buyer in Q3 2019 was Virtu Financial, an estimated $2.84M added.
- The largest VanEck Biotech ETF seller in Q3 2019 was Traphagen Investment Advisors, an estimated $6.34M sold.
Based on aggregated 13F filings for Q3 2019.